A detailed history of Regatta Capital Group, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Regatta Capital Group, LLC holds 11,485 shares of ABBV stock, worth $2.08 Million. This represents 0.45% of its overall portfolio holdings.

Number of Shares
11,485
Previous 11,780 2.5%
Holding current value
$2.08 Million
Previous $2.02 Million 12.28%
% of portfolio
0.45%
Previous 0.44%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

SELL
$163.84 - $199.33 $48,332 - $58,802
-295 Reduced 2.5%
11,485 $2.27 Million
Q2 2024

Aug 02, 2024

SELL
$154.79 - $180.76 $107,114 - $125,085
-692 Reduced 5.55%
11,780 $2.02 Million
Q1 2024

Apr 23, 2024

BUY
$159.82 - $182.1 $3,196 - $3,642
20 Added 0.16%
12,472 $2.27 Million
Q4 2023

Jan 22, 2024

BUY
$137.6 - $154.97 $6,054 - $6,818
44 Added 0.35%
12,452 $1.93 Million
Q3 2023

Oct 30, 2023

SELL
$133.59 - $154.65 $27,653 - $32,012
-207 Reduced 1.64%
12,408 $1.85 Million
Q2 2023

Jul 13, 2023

SELL
$132.51 - $164.9 $70,230 - $87,397
-530 Reduced 4.03%
12,615 $1.7 Million
Q4 2022

Feb 07, 2023

SELL
$138.31 - $165.87 $20,054 - $24,051
-145 Reduced 1.09%
13,145 $2.13 Million
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $334,719 - $383,901
2,494 Added 23.1%
13,290 $2.04 Million
Q2 2022

Aug 09, 2022

SELL
$137.62 - $174.96 $326,297 - $414,830
-2,371 Reduced 18.01%
10,796 $1.65 Million
Q1 2022

May 16, 2022

SELL
$131.98 - $163.75 $176,589 - $219,097
-1,338 Reduced 9.22%
13,167 $2.14 Million
Q4 2021

Feb 23, 2022

BUY
$107.43 - $135.93 $1.56 Million - $1.97 Million
14,505 New
14,505 $1.96 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $320B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Regatta Capital Group, LLC Portfolio

Follow Regatta Capital Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Regatta Capital Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Regatta Capital Group, LLC with notifications on news.